Czeizel A E, Tóth M, Rockenbauer M
Department of Human Genetics and Teratology, National Institute of Public Health/World Health Organization Collaborating Centre for the Community Control of Hereditary Diseases, Budapest, Hungary.
Epidemiology. 1999 Jul;10(4):437-40. doi: 10.1097/00001648-199907000-00013.
We evaluated the potential teratogenic effects of vaginal and/or topical administration of clotrimazole in the large population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities (1980-1992). The dataset included 18,515 case pregnancies and 32,804 control pregnancies; 7.1% of case and 7.7% of control women used clotrimazole during pregnancy. Clotrimazole use was not clearly associated with an increase in the total (fetal + birth) prevalence of any congenital abnormality group. There was, however, a suggestion that clotrimazole use was associated with a decrease in the prevalence of undescended testis (prevalence odds ratio = 0.72; 95% confidence interval = 0.54-0.95).
我们在匈牙利先天性异常病例对照监测的大型人群数据集（1980 - 1992年）中，评估了阴道和/或局部使用克霉唑的潜在致畸作用。该数据集包括18515例病例妊娠和32804例对照妊娠；7.1%的病例组妇女和7.7%的对照组妇女在孕期使用了克霉唑。克霉唑的使用与任何先天性异常组的总（胎儿期 + 出生时）患病率增加并无明显关联。然而，有迹象表明，使用克霉唑与隐睾患病率降低有关（患病率比值比 = 0.72；95%置信区间 = 0.54 - 0.95）。
